Statin induced myopathy

The use of statins has grown to over 100 million prescriptions per year since their introduction for the treatment of hypercholesterolemia in 1987. As a conservative estimate, at least 1.5 million people per year will experience a muscle related adverse event while taking a statin. Here, Sathasivam and Lecky discuss statin induced myopathy and its management in the light of recent epidemiological studies, randomized controlled trials, and guidelines. Moreover, they point out that if a patient presents with features suggesting statin induced myopathy, first line management is to stop statin therapy and observe any effect on symptoms and concentration of creatine kinase.